Evidence map›Paper›PMID 35419310›Full record

ArticleTranslational and clinical pharmacology2022

Prediction of metabolizing enzyme-mediated clinical drug interactions using

Suein Choi, Dong-Seok Yim, Soo Hyeon Bae

Abstract read
In one paragraph

Article in Translational and clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The In Vitro Pharmacokinetics of Medicinal Plants: A Review.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Suein ChoiDepartment of Clinical Pharmacology and Therapeutics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID https://orcid.org/0000-0001-5438-7819
Dong-Seok YimDepartment of Clinical Pharmacology and Therapeutics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID https://orcid.org/0000-0003-2754-7500
Soo Hyeon BaeQfitter Inc., Seoul 06578, Korea.ORCID https://orcid.org/0000-0001-5896-5938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluation of drug interactions is an essential step in the new drug development process. Regulatory agencies, including U.S. Food and Drug Administrations and European Medicines Agency, have been published documents containing guidelines to evaluate potential drug interactions. Here, we have streamlined

Indexed as

Cytochrome P-450 Enzyme InducersCytochrome P-450 Enzyme InhibitorsDrug InteractionsMetabolism

Identifiers

PMID35419310
PMCPMC8979758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.